Iktar informazzjoni ― Malti

Urticaria komunement jippreżenta welts mgħollija b'ħakk intens. Xi drabi tkun akkumpanjata minn nefħa tat-tessuti ta 'taħt. It-trattament primarjament jinvolvi l-evitar ta' triggers, jekk magħruf. Medikazzjoni tal-ewwel linja tinkludi anti-istaminiċi aktar ġodda, li jistgħu jiġu aġġustati għal dożi ogħla jekk meħtieġ. Mediċini oħra bħall-anti-istaminiċi anzjani, imblokkaturi H2, antagonisti tar-riċetturi tal-leukotriene, anti-istaminiċi aktar b'saħħithom, u korsijiet qosra ta 'kortikosterojdi jistgħu jiżdiedu bħala appoġġ addizzjonali. F'każijiet fejn l-urtikarja tippersisti minkejja dawn il-miżuri, il-pazjenti jistgħu jiġu riferuti għand speċjalisti għal terapiji addizzjonali bħal omalizumab jew cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Din ir-reviżjoni tiddeskrivi l-aħħar linji gwida għat-trattament tal-urtikarja u toffri fehim ġdid tal-kawżi tagħha.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids